INTRODUCTION {#S1}
============

Mis-expression of the double homeobox transcription factor *DUX4* in skeletal muscle is the cause of facioscapulohumeral muscular dystrophy (FSHD) ([@R32]). In cultured FSHD muscle cells, there is a de-repression of the *DUX4* retrogene, resulting in a burst of *DUX4* expression from a minority of myonuclei. In contrast to the toxicity of *DUX4* expression in skeletal muscle cells, *DUX4* is normally expressed in the early cleavage-stage embryo, where it regulates zygotic genome activation ([@R3]; [@R9]; [@R35]). In both of these cases, the burst expression of *DUX4* results in a perdurant developmental or pathological phenotype. This could be due to the initiation of a transcription factor cascade, an induced chromatin memory, or both.

Histone variants play critical roles in early development, such as the recently demonstrated requirement for *H3.3* in paternal genome activation in mouse preimplantation embryos ([@R13]) as well as for retroelement silencing in embryonic stem cells ([@R5]). Although canonical H3 is incorporated into newly synthesized DNA, H3.3 and H3.3 variants are made throughout the cell cycle ([@R1]) and use either the ATRX/DAXX complex to incorporate into repressed regions ([@R4]; [@R8]; [@R20]) or the HIRA chaperone to incorporate into transcriptionally active DNA ([@R2]; [@R31]). Canonical H3 and H3.3 are extremely well conserved and differ by only 4 to 5 amino acids. More divergent histone variants, such as CENP-A and H3t, have more specialized roles in designating centromeres or facilitating the transition from histones to protamines during spermiogenesis, respectively ([@R10]; [@R30]).

Histone variants *H3.X* and *H3.Y* were recently identified in the human genome as a multicopy gene family interspersed with the *TAF11-like* macrosatellite repeat ([@R37]). Biochemical studies of H3.Y nucleosomes showed that they resulted in a more relaxed chromatin configuration than H3.3 nucleosomes, excluded linker histone H1, were incorporated at transcriptional start sites (TSSs) of actively transcribed genes, and that H3.Y used the HIRA chaperone ([@R16]; [@R41]). Collectively, these data suggest that H3.Y, and possibly H3.X as well, might be incorporated at active genes and help to maintain an open chromatin conformation.

Here, we show that DUX4 induces the expression of *H3.X* and *H3.Y* and that these histone variants are incorporated in highly transcribed DUX4 target genes. A short pulse of *DUX4* that mimics its developmental expression pattern induced *H3.X/Y* expression and the majority of DUX4-regulated genes but was not cytotoxic, permitting the analysis of longer term consequences of DUX4 expression. DUX4-induced expression of *H3.X/Y* resulted in greater perdurance of DUX4 target gene expression and enhanced activation with a second pulse of *DUX4*. Together, these results indicate that incorporation of H3.X/Y at DUX4-induced genes contributes to prolonged expression and sensitizes these genes to subsequent induction.

RESULTS {#S2}
=======

DUX4 Induces the Expression of Histone Variants *H3.X* and *H3.Y* {#S3}
-----------------------------------------------------------------

To study the transcriptional network activated by DUX4, we have used a well-characterized cellular model system of human myoblasts with a doxycycline-inducible *DUX4* transgene (MB135iDUX4 cells; [@R11]). Induction of *DUX4* in these cells has been shown to induce many DUX4-regulated genes belonging to the transcriptional program characteristic of the early cleavage-stage embryo ([@R9]; [@R35]) and recapitulates the transcriptional consequences of endogenous *DUX4* expression in FSHD cells ([@R11]; [@R38]). As such, it is a validated model system for the identification of DUX4-regulated genes and the biological consequences of *DUX4* expression.

Further analysis of our previous RNA sequencing datasets ([@R11]) revealed high expression of unannotated transcripts in the region of the *TAF11-like* macrosatellite repeat array on chromosome 5 that were not detected in the absence of *DUX4* induction. Some of these sequences correspond to histone variants *H3.X* and *H3.Y* ([@R37]), as well as a previously unreported related sequence we designated *H3.Z* ([Figure S1A](#SD1){ref-type="supplementary-material"}). Chromatin immunoprecipitation sequencing (ChIP-seq) ([@R7]) showed DUX4 binding near the TSS of *H3.X*, *H3.Y*, and *H3.Z* loci ([Figures 1A](#F1){ref-type="fig"} and [S1D](#SD1){ref-type="supplementary-material"}), suggesting they are direct targets of DUX4. Compared to *H3.X* or *H3.Y*, *H3.Z* has a frameshift mutation that disrupts the histone fold and produces a longer protein ([Figures S1A](#SD1){ref-type="supplementary-material"} and [S1B](#SD1){ref-type="supplementary-material"}). Although overexpression of *H3.X* or *H3.Y* in myoblasts resulted in nuclear staining, overexpression of *H3.Z* did not ([Figure S1C](#SD1){ref-type="supplementary-material"}), suggesting H3.Z does not generate a functional histone protein. Therefore, moving forward, we focused our efforts on the characterization of DUX4-induced expression of *H3.X* and *H3.Y*.

Western analysis with an antibody to an epitope shared by *H3.X*, *H3.Y*, and *H3.Z* ([@R37]) detected both H3.X and H3.Y between 8 and 16 h after *DUX4* induction in MB135iDUX4 cells, with levels increasing up to 24 h ([Figure 1B](#F1){ref-type="fig"}). H3.X is slightly larger than H3.Y, as shown by *in vitro* translated protein, generating a closely spaced doublet. In addition to H3.X and H3.Y (see lanes labeled X and Y in [Figure 1B](#F1){ref-type="fig"}), a band migrating at the size of H3.Z was also detected.

To determine whether endogenous DUX4 also regulated *H3.X/Y*, we used myoblast cell lines derived from individuals with FSHD1 and FSHD2, the two forms of the disease ([@R32]), which show sporadic de-repression of *DUX4* in \~0.1% of cells ([@R29]), with increasing frequency and amount of *DUX4* expression upon differentiation to myotubes ([@R12]; [@R15]; [@R29]). qRT-PCR detected elevated levels of *DUX4*, *H3.X*, *H3.Y*, and *H3.Z* in both FSHD1 and FSHD2 myoblast cultures, but not in controls, with increased expression in the FSHD myotubes ([Figures 1C](#F1){ref-type="fig"} and [S1E](#SD1){ref-type="supplementary-material"}). Immunofluorescence showed strong nuclear H3.X/Y staining in FSHD myoblasts and myotubes, which also co-localized with DUX4 staining, whereas no control myoblasts or myotubes stained positively for either H3.X/Y or DUX4 ([Figures 1D](#F1){ref-type="fig"} and [1E](#F1){ref-type="fig"}).

During embryonic development, *DUX4* is expressed in a short burst during the cleavage stage ([@R9]). Re-analysis of human embryo RNA sequencing (RNA-seq) data ([@R9]) revealed that expression of *H3.X* and *H3.Y* coincided with *DUX4* expression ([Figure 1F](#F1){ref-type="fig"}). Together, these data identify *H3.X* and *H3.Y* as genes regulated by DUX4 and show that they are co-expressed with endogenous DUX4 in biologically relevant contexts, i.e., FSHD muscle cells and the cleavage-stage human embryo. In addition, we have previously shown *DUX4* expression in the testis ([@R29]), where *H3.X/Y* expression has also been reported ([@R37]).

H3.X/Y Are Incorporated in Expressed Regions of the Genome {#S4}
----------------------------------------------------------

Previous studies demonstrated that exogenously expressed H3.Y was incorporated into nucleosomal DNA by the HIRA chaperone complex ([@R41]) at the TSSs of highly expressed genes ([@R16]; [@R41]). To determine the incorporation pattern of endogenous H3.X/Y in DUX4-expressing cells, we induced *DUX4* in MB135iDUX4 myoblasts and used the antibody-targeted micrococcal nuclease (MNase) CUT&RUN assay ([@R28]; [@R27]) to map H3.X/Y incorporation genome-wide (schematic in [Figure 2A](#F2){ref-type="fig"}). H3.X/Y localized in domains ranging from 500 bp to nearly 100 kb ([Figure S2A](#SD1){ref-type="supplementary-material"}), with \~75% of domains overlapping genic regions and the remaining 25% intergenic ([Figure 2B](#F2){ref-type="fig"}), similar to what was seen in a previous study using ChIP-seq of tagged H3.Y expressed in HeLa cells ([@R41]).

H3.X/Y were preferentially incorporated at highly expressed genes ([Figure 2C](#F2){ref-type="fig"}) and at DUX4-induced target genes ([Figure 2D](#F2){ref-type="fig"}). Similarly, 80% of intergenic DUX4-induced long noncoding RNAs (lncRNAs, n = 380) showed H3.X/Y incorporation, and the presence of an intergenic H3.X/Y domain correlated with induction by DUX4 as compared to random intergenic bins of comparable length ([Figure 2E](#F2){ref-type="fig"}). Specific examples of DUX4-induced genes and constitutively expressed genes are shown in [Figures 2F](#F2){ref-type="fig"} and [2G](#F2){ref-type="fig"}, respectively. Averaging over larger sets of genes showed greater H3.X/Y enrichment at the TSSs of constitutively expressed genes ([Figure 2H](#F2){ref-type="fig"}, left), consistent with previous reports ([@R16]; [@R41]), whereas H3.X/Y were enriched throughout the entire transcribed region of DUX4-induced genes ([Figure 2H](#F2){ref-type="fig"}, right).

A Pulse of DUX4 Activates Target Gene Expression with Little Cell Toxicity {#S5}
--------------------------------------------------------------------------

Mis-expression of *DUX4* induces apoptotic cell death in nearly every cell type tested ([@R14]; [@R24]; [@R34]), yet DUX4 is expressed in the germline and early embryo ([@R9]; [@R29]), and the Dux mouse ortholog was shown to be important for early embryo development ([@R3]). Unlike in cell culture models, where toxicity occurs with continuous *DUX4* expression, *DUX4* is only briefly expressed in the early embryo. To test whether cells might survive transient expression of DUX4, we treated MB135iDUX4 myoblasts with a 4- to 6-h "pulse" of doxycycline to induce transient *DUX4* expression. In contrast to the continuous expression of *DUX4* that resulted in the death of nearly the entire cell population by 48--72 h, a 4-h pulse of doxycycline resulted in only a small reduction of the cell population at 24 h followed by expansion of that population through the 72-h time point ([Figure 3A](#F3){ref-type="fig"}). Immunodetection showed that a short pulse of doxycycline induced DUX4 expression in nearly all nuclei ([Figure 3B](#F3){ref-type="fig"}). Western analysis confirmed that *DUX4* protein and *DUX4* targets ZSCAN4 and H3.X/Y/Z were detectable at similar time points as observed for continuous DUX4 expression and persisted for at least 24 h ([Figure 3C](#F3){ref-type="fig"}; compare to [Figure 1B](#F1){ref-type="fig"}). Remarkably, the H3.X and H3.Y proteins remained detectable even 4 days after the initial pulse ([Figure 3D](#F3){ref-type="fig"}). Based on RNA-seq analysis, the transcriptome 24 h after a pulse of *DUX4* largely recapitulated the transcriptional changes characterized by the continuous expression of *DUX4* seen in [@R11]; R^2^ = 0.63; [Figure 3E](#F3){ref-type="fig"}. Of the 941 genes that increased by a log2 fold-change \> 2.0 (adjusted p \< 0.05) in the continuous sample, 673 (72%) showed greater than a two-fold change (log2 fold-change \> 1.0) 24 h after beginning a 4-h pulse of *DUX4* ([Table S1](#SD2){ref-type="supplementary-material"} and red dots in [Figure 3E](#F3){ref-type="fig"}). These results suggest that the duration of *DUX4* expression might be a major determinant of toxicity rather than the cell type and that a brief pulse of DUX4 results in robust activation of its transcriptional program and prolonged presence of H3.X/Y proteins.

H3.X/Y Incorporation Increases the Perdurance and Re-expression of DUX4 Target Genes {#S6}
------------------------------------------------------------------------------------

To determine whether H3.X/Y incorporation at DUX4 target genes could increase perdurance of gene expression and/or facilitate subsequent gene expression, we induced a pulse of *DUX4* followed by a second pulse 2 days later, when H3.X/Y are present in chromatin ([Figure 4A](#F4){ref-type="fig"}). We compared gene expression with or without H3.X/Y by using small interfering RNAs (-siRNAs) that targeted both *H3.X* and *H3.Y* (siXY) or control siRNA (siControl; [Figures 4A](#F4){ref-type="fig"}-[4D](#F4){ref-type="fig"}). RNA for the DUX4 targets *ZSCAN4* and *TRIM43*, both of which overlap with H3.X/Y incorporation (see [Figure 2F](#F2){ref-type="fig"}), were robustly induced 24 h after the first pulse of *DUX4* expression with decreased levels by 48 h after the pulse. A second pulse of *DUX4* 2 days after the first pulse invoked a super-induction of *ZSCAN4* and *TRIM43* 24 h later (day 3), with RNA levels roughly six-fold greater than after the single pulse. Despite similar, or slightly higher, levels of *DUX4* expression ([Figure 4B](#F4){ref-type="fig"}), *H3.X/Y* knockdown prevented this super-induction after the second pulse ([Figure 4C](#F4){ref-type="fig"}). Following either the first pulse or second pulse of *DUX4*, *ZSCAN4* and *TRIM43* had greater perdurance of expression in siControl-treated cells compared to siXY-treated cells based on both the amount of RNA and the slope of the decline of mRNA ([Figure 4D](#F4){ref-type="fig"}). This suggests that incorporation of H3.X/Y facilitated the increased inducibility of these genes and the persistence of their RNA expression. In contrast to these DUX4 target genes, constitutively expressed genes that incorporated H3.X/Y, e.g., *TPT1* and *XRCC5*, were unaffected by H3.X/Y knockdown ([Figures S2B](#SD1){ref-type="supplementary-material"} and [S2C](#SD1){ref-type="supplementary-material"}). Overexpression of FLAG-tagged H3.X or H3.Y in the absence of DUX4 did not induce DUX4 target gene expression ([Figures S3A](#SD1){ref-type="supplementary-material"}-[S3C](#SD1){ref-type="supplementary-material"}), indicating that H3.X/Y were enhancing the response to DUX4 rather than acting alone to induce a transcriptional response. Similar to the results in myoblasts, H3.X/Y expression was necessary for enhanced induction of DUX4 target genes following a second pulse of DUX4 in differentiated muscle cells ([Figures S4A](#SD1){ref-type="supplementary-material"} and [S4B](#SD1){ref-type="supplementary-material"}), consistent with replication-independent nucleosome incorporation mediated by the HIRA chaperone. Furthermore, H3.X/Y knockdown in FSHD1 and FSHD2 myoblasts or myotubes decreased both DUX4 expression and DUX4 target gene expression ([Figures S4C](#SD1){ref-type="supplementary-material"}-[S4E](#SD1){ref-type="supplementary-material"}).

Expanding these experiments genome-wide, we performed RNA-seq 24 h after the 1-pulse and 2-pulse time points for the conditions shown in [Figure 4A](#F4){ref-type="fig"}. Differential gene expression analysis revealed that H3.X/Y were necessary to sensitize nearly all DUX4-induced genes for subsequent super-induction. A single pulse of *DUX4* showed induction of target genes ([Figure 4Ei](#F4){ref-type="fig"}) that were not affected by *H3.X/Y* knockdown ([Figure 4Eii](#F4){ref-type="fig"}), whereas super-induction of DUX4 target genes with a second pulse ([Figure 4Eiii](#F4){ref-type="fig"}) was prevented by *H3.X/Y* knockdown ([Figure 4Eiv](#F4){ref-type="fig"}). In contrast, constitutively expressed non-DUX4 targets with H3.X/Y incorporation were unaffected by pulses of *DUX4* and knockdown treatments ([Figure 4F](#F4){ref-type="fig"}). These results demonstrate that H3.X and H3.Y were incorporated into DUX4-induced genes and that this enhanced future expression of these genes.

DISCUSSION {#S7}
==========

Together, our data demonstrate that *H3.X* and *H3.Y* are induced by DUX4 in human muscle cells, are induced coincident with *DUX4* expression in human embryos and in FSHD muscle cells, are incorporated at genes induced by DUX4, and that their incorporation both promotes the perdurance of DUX4 target gene expression and facilitates their subsequent induction. Previously, other groups have described important biochemical properties of H3.X and H3.Y, mostly through *in vitro* and mis-expression studies ([@R16], [@R17]; [@R37]; [@R41]). In particular, the *in vitro* biochemical studies predicting a more relaxed chromatin state with less efficient H1 binding ([@R16]) are consistent with our studies in a DUX4-inducible myoblast cell line showing enhanced transcription of genes incorporating H3.X/Y. In this way, our study builds on these important advances and characterizes biological consequences of endogenous H3.X/Y expression. Future studies will be needed to determine the role of H3.X/Y incorporation during embryogenesis and whether H3.X/Y contribute to FSHD pathophysiology.

In contrast to DUX4 target genes, constitutively expressed genes were mostly unaffected by incorporation of H3.X/Y. This was also associated with a different pattern of incorporation. Whereas H3.X/Y were incorporated throughout the gene body of DUX4 target genes, incorporation at constitutively expressed genes was largely flanking the TSSs, as was previously reported in studies that mis-expressed H3.Y in HeLa cells ([@R16]; [@R41]). It is possible that this different pattern of incorporation represents the difference between a constitutively expressed gene and an induced but previously silent gene. Because the majority of genes robustly regulated by DUX4 are not expressed in myoblasts, their nucleosomes would likely have canonical H3 histones that would be replaced with H3.X/Y and H3.3 when actively transcribed. In contrast, constitutively expressed genes would already have replaced canonical H3 histones with H3.3 and there might be less turnover in the gene body compared to newly induced genes, restricting H3.X/Y incorporation to nucleosomes flanking the TSS that undergo more rapid turnover. Although speculative, this difference might account for the specificity of perdurance and hyper-induction at DUX4-induced genes that incorporate H3.X/Y.

Another important finding of our study is that skeletal muscle cells survive the DUX4-induced transcriptional program following a transient burst of *DUX4* expression. Using a well-characterized cell culture model ([@R11]) with inducible *DUX4*, it was possible to mimic the kinetics of embryonic *DUX4* expression with short pulses, leading to expression of targets, including *H3.X/Y*, without inducing cell death. This made it feasible to study the effects of *DUX4* expression over several days. This finding has interesting implications for both stem cell biology and FSHD muscular dystrophy. In stem cell biology, brief expression of *DUX4* similar to that in the early embryo occurs in a subset of embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), where it also induces a transcriptional program similar to the cleavage-cell state ([@R9]; [@R35]; [@R3]). Therefore, our findings suggest that the difference between the early embryo or ESCs/iPSCs that survive *DUX4* expression and FSHD cells or other somatic cells that die when *DUX4* is constitutively expressed might be the duration of expression rather than a protective factor unique to the early developmental program.

In this regard, skeletal muscle might be particularly susceptible to repeated bursts of *DUX4* expression. As our study has demonstrated, incorporation of H3.X/Y in DUX4 target genes increased the perdurance of their expression and enhanced subsequent activation ([Figure S4F](#SD1){ref-type="supplementary-material"}). Because H3.X/Y use the HIRA chaperone ([@R16]; [@R41]), they are incorporated into actively transcribed regions independent of DNA replication. As skeletal muscle is post-mitotic and multinucleated, H3.X/Y incorporation could create a prolonged sensitivity for DUX4 target expression, both in the nucleus that initially expressed *DUX4* and in adjacent nuclei that received DUX4 and H3.X/Y from their shared cytoplasm. In this model, stochastic bursts of *DUX4* in different nuclei in a myotube might result in progressive accumulation of H3.X/Y in an expanding nuclear domain and progressive enhancement of expression of DUX4 target genes, resulting in toxicity like that seen with the constitutive expression of *DUX4* ([Figure S4G](#SD1){ref-type="supplementary-material"}, right). In contrast, incorporation of H3.X/Y following the embryonic burst of *DUX4* would be diluted by subsequent cell divisions ([Figure S4G](#SD1){ref-type="supplementary-material"}, left). Initially, this could result in greater perdurance of the DUX4-induced transcriptional program but ultimately not reach toxic levels. It is important to emphasize that these models depict possible biological implications of H3.X/Y function based on data from cell culture studies of DUX4 expression in an engineered cell line and FSHD muscle cells. It will require future studies to verify the details of each model. For example, the burst of DUX4 at the four-cell stage in human embryos is documented ([@R9]), whereas subsequent bursts of DUX4 in the progeny of these cells has not been described and has yet to be carefully evaluated. Similarly, although H3.X/Y appear to have a role in DUX4 target gene expression in our cell culture models of FSHD, it remains to be shown whether H3.X/Y contribute to FSHD pathophysiology.

STAR★METHODS {#S8}
============

LEAD CONTACT AND MATERIALS AVAILABILITY {#S9}
---------------------------------------

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Stephen Tapscott (<stapscot@fredhutch.org>). In some cases, the Fred Hutchinson Cancer Research Center might require a standard Material Transfer Agreement.

EXPERIMENTAL MODEL AND SUBJECT DETAILS {#S10}
--------------------------------------

The following cell lines were used in this study: MB135 (control, female, ([@R7]), 54-1 (control, male, ([@R15]), MB073 (FSHD1, male, Fields Center for FSHD and Neuromuscular Research), 54-2 (FSHD1, male, ([@R15]), MB200 (FSHD2, male, Fields Center for FSHD and Neuromuscular Research), and 2453 (FSHD2, male, Fields Center for FSHD and Neuromuscular Research). FSHD, control, and MB135iDUX4 myoblasts (described in [@R11]) were grown in F10 growth medium (GIBCO Life Technologies) supplemented with 10% FBS (HyClone), 1% pen/strep (Life Technologies), 10pg/mL fgf (Life Technologies), 1 μM dexamethasone (Sigma), and 2 μg/mL puromycin or 10 μg/mL blasticidin as appropriate to maintain inducibility of the DUX4 transgene. FSHD and control cells were differentiated by growing to confluence and changing to differentiation medium: DMEM (GIBCO) with 1% horse serum (Life Technologies), 1% pen/strep, and 10 μM each transferrin and insulin for 72 h. Pulsed MB135iDUX4 cells were treated with 1 μg/mL doxycycline in growth medium for 6 h for RNA-seq experiments or 4 h for all other experiments, rinsed with PBS, and fresh growth medium added. Cells with continuous induction were treated with 1 μg/mL doxycycline in growth medium overnight or as specified. Differentiated MB135iDUX4 cells were treated with 2μg/mL doxycycline in differentiation medium for 8 h. All cell lines were cultured at 37°C in a humidified incubator supplied with 5% CO~2~.

METHOD DETAILS {#S11}
--------------

### siRNA treatment {#S12}

siRNAs for H3.X/Y were designed using the Dharmacon siDESIGN Center. Two siRNAs that gave \>90% knockdown were pooled for all experiments to minimize off-target effects with a non-targeting siRNA (Dharmacon D-001210-02-05) used as a control. For pulse experiments, cells were transfected with 50 pg siRNA in OPTIMEM with 7.5 μL Lipofectamine RNAiMax 16 h before each doxycycline treatment. For knockdown experiments in FSHD cells, a double transfection protocol was followed to ensure efficient depletion of pre-existing proteins. FSHD myoblasts were seeded in six-well plates and transfected the next day with 7.5 μL Lipofectamine RNAiMAX and 50pmol of either H3.X/Y-specific siRNA or a non-silencing control siRNA (Dharmacon D-001810-01) diluted in 500 μL OptiMEM Reduced Serum Medium (Thermo Fisher Scientific). Sixteen-hours post-transfection, media was replaced with either supplemented F10 growth media for myoblasts or serum-free differentiation media to promote myotube formation. Forty-eight h following the first transfection, cells were transfected with siRNAs a second time. Fresh media was added 16-hours post-transfection. Cells were harvested for RNA analysis or fixed for immunofluorescence 32 h later.

### CUT&RUN-sequencing {#S13}

MB135iDUX4 cells were treated with or without doxycycline for 18 h before harvesting. Protocol was followed as in [@R28] with modifications to scale up for 5 million cells per sample. 100 μL beads were used per sample and wash/incubation volumes were increased to 300-500 μL. 0.05% digitonin was used in the wash buffer. 15 μL H3.X/Y primary antibody (clone 8H6-2111, Active Motif 61161) was used per H3.X/Y sample and incubated for 2 hr. 25 μL rabbit anti-rat secondary (ab6703) was added to each sample for 1 hr. After MNase digestion, fragments were liberated for 20 min and DNA was then purified using the phenol/chloroform method. Three biological replicates were performed for H3.X/Y samples, both with and without doxycycline, and one replicate for each IgG condition.

### RNA isolation and sequencing {#S14}

MB135iDUX4 cells were treated with siRNA knockdown as described above followed by DUX4 pulsing, either once or twice, in triplicate, and harvested 24 h after the start of a pulse. Untreated cells were also harvested from triplicate wells as negative controls. The NucleoSpin RNA kit (Macherey-Nagel) was used to extract RNA from whole cells, following the manufacturer's instructions. RNA-seq libraries were prepared using the Illumina TruSeq RNA Sample Prep v2 Kit and a PerkinElmer Sciclone NGSx Workstation. All 15 libraries were pooled and sequenced on two flow lanes. The in-house R package and bioinformatics analysis were done with R-3.4.3/Bioconductor-3.5.

### Western blotting {#S15}

Protein was directly lysed from tissue culture plates using 2X Laemlli Buffer with 4% beta mercaptoethanol, sonicated, and boiled for 10 min. Samples were loaded on 4%--12% polyacrylamide gel (Novex) and run with MES buffer, then transferred to a PVDF membrane. Membranes were blocked in 5% milk in PBST for 1 h and incubated with primary antibody in 5% milk overnight at 4° (see [KEY RESOURCES TABLE](#T1){ref-type="table"} for details on antibodies). After washing, membranes were incubated with appropriate secondary antibodies for 1 h, washed, and detected with chemiluminescence on film.

### Reverse transcription and qPCR {#S16}

RNA was extracted as described for RNA-seq, treated with DNase I (ThermoFisher), and heat inactivated. 500ng-1 μg of RNA was reverse transcribed using SuperScript III First Strand cDNA Synthesis (ThermoFisher) according to manufacturer's instructions, using oligo-dT priming. A no-enzyme sample was also run with a mix of all RNA samples as a control. qPCR was performed using 1x iTaq SYBR Green Master Mix (Bio-Rad) and primers at 1 μM each. Primers listed in [Table S2](#SD3){ref-type="supplementary-material"}.

### Immunofluorescence {#S17}

Briefly, cells were fixed in 1% formaldehyde for 15 min, permeabilized in PBST, and incubated overnight with primary antibodies. Plates were then washed with PBS, incubated 1 h with fluorescent secondary antibody, counter-stained with DAPI, and imaged using an immersion lens.

### Cloning and polyclonal transgenic cell lines {#S18}

A putative *H3.Z* sequence was identified from RNA-seq reads and used to design primers slightly outside this region. Amplicons from cDNA of *DUX4*-expressing cells were individually subcloned using the TOPO system, miniprepped using the NucleoSpin Plasmid kit (Macherey-Nagel) according to manufacturer's instructions, and Sanger sequenced to generate the final *H3.Z* sequence. FLAG-tagged *H3.X*, FLAG-tagged *H3.Y*, *H3.Z*, and *GFP* were cloned into pCW57.1 (Addgene \#41393). Lentivirus with inducible transgenes were generated by co-transfecting 293T cells with FLAG-tagged H3 variant constructs, pMD2.G (Addgene \#12259) and psPAX2 (Addgene \#12260) using lipofectamine 2000 (ThermoFisher). To generate polyclonal lines, MB135 cells were transduced with lentivirus. Stable cell lines were selected and maintained in 2 μg/mL puromycin.

QUANTIFICATION AND STATISTICAL ANALYSIS {#S19}
---------------------------------------

### Relative quantitation of gene expression {#S20}

Quantitative PCR was carried out on a QuantStudio 7 Flex (Applied Biosystems). Relative expression levels of target genes were normalized to that of reference housekeeping gene *RPL-27* using the relative standard curve method ([Figures 4A](#F4){ref-type="fig"}-[4C](#F4){ref-type="fig"}, [S2B](#SD1){ref-type="supplementary-material"}, [S2C](#SD1){ref-type="supplementary-material"}, and [S4B](#SD1){ref-type="supplementary-material"}) or by using the Comparative Ct Method (ΔΔCt; [Figures 1C](#F1){ref-type="fig"}, [S1E](#SD1){ref-type="supplementary-material"}, [S4D](#SD1){ref-type="supplementary-material"}, and [S4E](#SD1){ref-type="supplementary-material"}). For [Figure 1C](#F1){ref-type="fig"}, samples were normalized to the average of all control replicates, and any samples from control lines that had undetectable signal were set to 0 and not used for normalizing. Information about statistical details can be found in the figure legends. Throughout, graphs represent means with error bars representing standard deviation (SD) of biological triplicate measurements.

### CUT&RUN domain calling {#S21}

Our CUT&RUN data consist of 25 bps long, paired-end reads with average fragment length of 180 bps. We aligned reads to both human genome hg38 and spike-in genome dm6 using Bowtie2-2.2.6 with the following comment: bowtie2--local--very-sensitive-local--no-unal--no-mixed--no-discordant -q-phred33 -I 10 -X 700.

Since H3.X/Y were incorporated in many large regions within gene bodies, conventional peak calling algorithms such as MACS2 were not applicable. We thus developed an in-house R/Bioconductor package *domainCalling* (<https://github.com/TapscottLab/domainCalling>). The major functionalities of *domainCalling* include spike-in factor normalization and domain (broad peak) detection. To call the domains, the algorithm starts by counting reads overlapping with a sliding window throughout the genome for non-background (DOX+) and background (IgG or DOX−) samples. This window-based counting scheme is implemented by the csaw R/Bioconductor package ([@R23]). After the counts are normalized by spike-in normalization, it filters out uninteresting windows if the average abundance of the non-background samples is (1) less than three-fold above background or (2) does not exceed the threshold, which is three reads per window. Finally, the retained windows are merged with neighbors within 2kbp distance. H3.X/Y domains were called for merged regions longer than 500 bps.

### RNA-seq data analysis of pulsed samples {#S22}

To preprocess the RNA-seq reads, we filtered out unqualified reads and aligned the reads to human genome hg38 using Tophat-2.1.0. We then profiled the gene expression using features collected from Ensembl v88 and the hit-counting function *summarizeOverlaps()* from Bioconductor's GenomicAlignments package. To identify robust DUX4 target genes, we used DESeq2 comparing pulse1 siControl samples to negative controls. The alternative hypothesis is set to ∣β∣ \> 4, where β denotes log2 fold change. 170 genes with adjusted p value \< 0.05 were determined as robust DUX4 targets.

### Statistical analysis of qPCR data {#S23}

To test the significance of the perdurance effect of H3.X/Y ([Figure 4D](#F4){ref-type="fig"}), we used functional data analysis (<https://cran.r-project.org/web/packages/fda/index.html>) treating the time course RT-qPCR expression data as a function or graph. The method started with registering the feature of the graph for each treatment, which was the day 1 data where the slope turned from positive to negative. Next it aligned the graphs of two groups of treatments at the value of the feature, and then, for each treatment, constructed a linear combination of functions interpolating the aligned time-course data starting from day 1 to day 4. Finally taken the null distribution built by 250 permutations, we applied the functional t test (fda::*tperm.fd*) to determine the difference between two groups of functions.

### Software {#S24}

The bioinformatics analysis was mostly performed on R-3.4.3/Bioconductor-3.5. The major infrastructure packages used include *csaw*, *edgeR*, *GenomicAlignments*, *ChIPseeker* and *ggplot2*.

DATA AND CODE AVAILABILITY {#S25}
--------------------------

The MB135iDUX4 pulsed RNA-seq data and CUT&RUN data generated during this study are available at the Gene Expression Omnibus (GEO accession number GSE119403). Other datasets used in this study include DUX4 ChIP-seq (GEO accession number GSE33838), continuous DUX4 RNA-seq (GEO accession number GSE85461), and early embryo RNA-seq (GEO accession number GSE72379). The H3.Z sequence shown in [Figure S1A](#SD1){ref-type="supplementary-material"} has been submitted to GenBank and is awaiting an accession number. Code availability is detailed in the [Key Resources Table](#T1){ref-type="table"} with the following references: ([@R18]; [@R19]; [@R22]; [@R25]; [@R26]; [@R39]; [@R40]).
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![DUX4 Induces the Expression of Histone Variants *H3.X* and *H3.Y*\
(A) RNA-seq (blue) and ChIP-seq (red) tracks from [@R11] and [@R7], respectively, showing that *H3.X* and *H3.Y* were induced with *DUX4* induction and that DUX4 was bound upstream of *H3.X* and *H3.Y*.\
(B) Western blot analysis of MB135iDUX4 time course after *DUX4* induction. H3.X and H3.Y migrate at slightly different sizes as shown by *in vitro* translated protein (lanes X and Y). The larger band corresponds to the predicted size for H3.Z. GAPDH(1) and GAPDH(2) represent loading controls for DUX4 or ZSCAN4 and H3.X/Y/Z, respectively.\
(C) qRT-PCR analysis of *DUX4*, *H3.X*, and *H3.Y* in control, FSHD1, and FSHD2 myoblasts and myotubes performed in biological triplicates. Values were normalized to the average of the control samples. ControlA = 54-1, ControlB = MB135, FSHD1 = 54-2, and FSHD2 = MB200.\
(D and E) Immunofluorescence of H3.X/Y (red) and DUX4 (green) in FSHD1, FSHD2, and control myoblasts and myotubes.\
(E) DUX4 and H3.X/Y co-stain rare FSHD myoblast cells and nuclei within myotubes, with no staining seen in control cells. DAPI channel in myoblasts and H3.X/Y and DUX4 channels in myotubes were brightened equally for all samples.\
(F) Average fragments per kilobase of transcript per million mapped reads (FPKM) of reads from indicated stages of early human embryos ([@R9]) that map to *H3.X*, *H3.Y*, and *DUX4*. Expression data displayed as mean with standard deviation of replicates.\
See also [Figure S1](#SD1){ref-type="supplementary-material"}.](nihms-1542960-f0002){#F1}

![H3.X/Y Are Incorporated in Expressed Regions of the Genome\
(A) Schematic of CUT&RUN protocol. H3.X/Y nucleosome is represented by a blue circle. CUT&RUN has been used successfully with antibodies that do not perform well in standard chromatin immunoprecipitation (ChIP) assays ([@R21]), and we used it for this study because the antibody to H3.X/Y did not work for standard ChIP.\
(B) Distribution of genomic annotations containing H3.X/Y domains.\
(C) Bar graph depicting association of XY incorporation and all DUX4-induced genes ([@R11]). Gene expression quantiles (log_10 RPKM quantile; y axis) are plotted against the percentage of genes in each quantile interval overlapping with H3.X/Y domains (x axis). Pearson correlation = 0.958.\
(D) Same as (C) for robust DUX4 target genes (n = 251 with adjusted p \< 0.05, corresponding to H_0: ∣lfc∣ \< 4). Pearson correlation = 0.976.\
(E) Histogram of intergenic region expression change with *DUX4* induction. Comparing intergenic H3.X/Y domains with random intergenic bins of comparable size shows an association between H3.X/Y domains and DUX4-induced transcription. Vertical dashed lines mark mean log2 fold change with DUX4 for each group.\
(F) DUX4 ChIP-seq ([@R7]), immunoglobulin G (IgG), or H3.X/Y CUT&RUN (C&R) and called H3.X/Y domains at DUX4 target genes *TRIM43* and *ZSCAN4*.\
(G) Same as (F) but for genes constitutively expressed (*TPT* and *RCN1*).\
(H) Analysis of the distribution of H3.X/Y CUT&RUN reads within genes. Left panel shows highly expressed, non-DUX4 target genes with H3.X/Y domains (n = 679); right panel shows DUX4 target genes only (n = 191).\
See also [Figure S2](#SD1){ref-type="supplementary-material"}.](nihms-1542960-f0003){#F2}

![A Pulse of *DUX4* Activates Target Gene Expression with Little Cell Toxicity\
(A) Counts of live MB135iDUX4 cells (cells that exclude trypan blue) before and at daily time points after continuous exposure to doxycycline (cont) or a 4-h pulse of doxycycline (pulse). T0, T24, T48, and T72 indicate the hours following initial doxycycline addition.\
(B) DUX4 and H3.X/Y immunofluorescence in MB135iDUX4 cells 8 h after the start of a 4-h pulse of doxycycline (pulse) shows induction in nearly all cells, with no staining in uninduced (no dox) cells.\
(C) Western blot analysis of MB135iDUX4 cells up to 24 h after *DUX4* pulse. Cells were induced from 0 to 4 h. H3.X/Y/Z are identified with colored arrowheads: H3.Z (green); H3.X (dark blue); and H3.Y (light blue).\
(D) MB135iDUX4 cells with control or *H3.X/Y* knockdown with 1 or 2 pulses of *DUX4* on days 0 and 2, respectively, and harvested 1--4 days after each pulse (days 1--4 for 1^st^ pulse; days 3--6 for 2^nd^ pulse). +, continuous dox overnight; --, uninduced day 0 cells. H3.X/Y/Z are identified as in (C).\
(E) Comparison of DUX4-induced genes from RNA-seq datasets in MB135iDUX4 cells after continuous (from [@R11]) or pulsed *DUX4* expression (log2-fold change over no *DUX4* induction with adjusted p \< 0.05). Axes show degree of gene induction (log2-fold change over no *DUX4*) with adjusted p \< 0.05 corresponding to H_0: ∣log2-fold change∣ \< 2. Green indicates genes activated less than 2-fold (log2-fold change \< 1.0) in the pulse condition, red indicates genes induced more than 2-fold in the pulse, and blue indicates genes induced by the pulse but less than 2-fold in the continuous.](nihms-1542960-f0004){#F3}

![H3.X/Y Incorporation Increases the Perdurance and Re-expression of DUX4 Target Genes\
(A) Schematic of experimental design.\
(B--D) qRT-PCR in MB135iDUX4 cells with 1 or 2 pulses of *DUX4* and treatment with siH3.X/Y (green) or siControl (blue). Cells were harvested before induction and 1--4 days after each pulse, with 3 biological replicates for each sample shown, relative to *RPL-27*.\
(D) Data from (C) plotted on a log scale illustrate differential perdurance of DUX4 target gene expression in siH3.X/Y relative to siControl samples (\*p \< 0.05; one-tailed Wilcoxon rank sum test). Based on a functional t test on the null distribution built by permutations (see [STAR Methods](#S8){ref-type="sec"}), the difference of the slopes between siControl and siH3.XY is significant (p \< 1e--12).\
(E) Expression of DUX4 targets measured by RNA-seq in MB135iDUX4 cells, shown as average log2 normalized read counts of biological triplicates. Sequences in the *H3.X/Y* family targeted by siXY are shown in blue. Null model (no difference between conditions) is shown in gray. (1) Induction of *DUX4* targets, (2) comparison of *H3.X/Y* and control knockdown with a single pulse, (3) super-induction of DUX4 targets with a second pulse in control knockdown samples, and (4) knockdown of *H3.X/Y* eliminating super-induction are shown.\
(F) Expression of genes with *H3.X/Y* domains that are unaffected by *DUX4*, plotted as in (E).\
See also [Figures S2](#SD1){ref-type="supplementary-material"} and [S4](#SD1){ref-type="supplementary-material"}.](nihms-1542960-f0005){#F4}

###### 

KEY RESOURCES TABLE

  REAGENT or RESOURCE                                                                      SOURCE                                              IDENTIFIER
  ---------------------------------------------------------------------------------------- --------------------------------------------------- --------------------------------------------------------------------------------------------------
  Antibodies                                                                                                                                   
  GAPDH (6C5)                                                                              GeneTex                                             GTX28245; RRID: AB_37067
  DUX4                                                                                     [@R6]                                               E14-3
  ZSCAN4                                                                                   ThermoFisher                                        PA5-32106; RRID: AB_2549579
  H3.X/Y                                                                                   [@R37]                                              clone 8H6-2111; Active Motif Cat\# 61161, RRID:AB_2793533
  FLAG                                                                                     Sigma                                               F3165
  Goat anti-rat                                                                            Jackson ImmunoResearch                              112-035-068
  Peroxidase AffiniPure Goat Anti-Rabbit (H+L)                                             Jackson ImmunoResearch                              111-035-144; RRID: AB_2307391
  Peroxidase AffiniPure Goat Anti-Mouse IgG (H+L)                                          Jackson ImmunoResearch                              115-035-146; RRID: AB_2307392
  Rhodamine (TRITC)-AffiniPure Donkey Anti-Rat IgG                                         Jackson ImmunoResearch                              712-025-150
  Fluorescein (FITC)-AffiniPure Donkey Anti-Rabbit IgG                                     Jackson ImmunoResearch                              711-095-152
  Rhodamine (TRITC)-AffiniPure Donkey Anti-Mouse IgG                                       Jackson ImmunoResearch                              715-025-151
  Bacterial and Virus Strains                                                                                                                  
  Stbl3 Competent *E. coli*                                                                Generated in-lab                                    N/A
  Chemicals, Peptides, and Recombinant Proteins                                                                                                
  DNase Amp grade                                                                          Invitrogen                                          18068015
  RNaseOUT Recombinant Ribonuclease Inhibitor                                              Invitrogen                                          10777019
  Oligo(dT) 12-18 Primer                                                                   Invitrogen                                          18418012
  Superscript III                                                                          Invitrogen                                          18080044
  Recombinant human basic fibroblast growth factor                                         Promega                                             G5071
  Dexamethasone                                                                            Sigma-Aldrich                                       D4902
  Puromycin dihydrochloride                                                                Sigma-Aldrich                                       P833
  Blasticidin                                                                              GIBCO                                               R21001
  Penicillin/streptomycin                                                                  GIBCO                                               15140122
  Doxycycline hyclate                                                                      Sigma-Aldrich                                       D9891
  Insulin                                                                                  Sigma-Aldrich                                       I1882
  Transferrin                                                                              Sigma-Aldrich                                       T-0665
  Polybrene                                                                                Sigma-Aldrich                                       107689
  Critical Commercial Assays                                                                                                                   
  Lipofectamine RNAiMAX                                                                    Life Technologies                                   13778150
  Lipofectamine 2000                                                                       ThermoFisher                                        11668019
  OptiMEM Reduced Serum Medium                                                             ThermoFisher                                        31985070
  iTaq SYBR Green Supermix                                                                 Bio-Rad                                             1725124
  NucleoSpin RNA kit                                                                       Machery-Nagel                                       740955
  Illumina TruSeq RNA Sample Prep v2 Kit                                                   Illumina                                            RS-122-2001
  Deposited Data                                                                                                                               
  DUX4 ChIP                                                                                [@R7]; NCBI GEO                                     GSE33838
  continuous DUX4 RNA-seq                                                                  [@R11]; NCBI GEO                                    GSE85461
  early human embryo RNA-seq                                                               [@R9]; NCBI GEO                                     GSE72379
  RNA-seq data for this study                                                              NCBI Gene Expression Omnibus                        GSE119403
  CUT&RUN data for this study                                                              NCBI Gene Expression Omnibus                        GSE119403
  Mendeley Dataset for this study                                                          <https://data.mendeley.com/>                        <https://doi.org/10.17632/8mvjj5rw6r.1>
  Experimental Models: Cell Lines                                                                                                              
  MB135 (female)                                                                           [@R7]                                               N/A
  54-1 (male)                                                                              [@R15]                                              N/A
  MB073 (male, FSHD1)                                                                      Fields Center for FSHD and Neuromuscular Research   <https://www.urmc.rochester.edu/neurology/fields-center.aspx>
  54-2 (male, FSHD1)                                                                       [@R15]                                              N/A
  MB200 (male, FSHD2)                                                                      Fields Center for FSHD and Neuromuscular Research   <https://www.urmc.rochester.edu/neurology/fields-center.aspx>
  2453 (male, FSHD2)                                                                       Fields Center for FSHD and Neuromuscular Research   <https://www.urmc.rochester.edu/neurology/fields-center.aspx>
  MB135iDUX4 (female)                                                                      [@R11]                                              N/A
  MB135iFLAG-H3.3 (female)                                                                 This Study                                          N/A
  MB135iFLAG-H3.X (female)                                                                 This Study                                          N/A
  MB135iFLAG-H3.Y (female)                                                                 This Study                                          N/A
  MB135iH3.Z (female)                                                                      This Study                                          N/A
  MB135iGFP (female)                                                                       This Study                                          N/A
  Oligonucleotides                                                                                                                             
  Primers for qPCR and cloning (see [Table S2](#SD3){ref-type="supplementary-material"})   This Study                                          N/A
  siRNAs targeting H3.X/Y: UCAAGAAGCCUCACCGCUAUU, GCGGGAAAUCAGAAAGUACUU                    This Study (Dharmacon Custom)                       N/A
  siGENOME non-Targeting \#2 Control siRNA                                                 Dharmacon                                           D-001210-02-20
  ON-TARGETplus Non-targeting \#1 Control siRNA                                            Dharmacon                                           D-001810-01
  Recombinant DNA                                                                                                                              
  pCW57.1                                                                                  Addgene                                             41397; RRID: Addgene_41397
  pMD2.G                                                                                   Addgene                                             12259
  psPAX2                                                                                   Addgene                                             12260
  pCW57.1-FLAG:H3.3                                                                        This Study                                          N/A
  pCW57.1-FLAG:H3.X                                                                        This Study                                          N/A
  pCW57.1-FLAG:H3.Y                                                                        This Study                                          N/A
  pCW57.1-H3.Z                                                                             This Study                                          N/A
  pCW57.1-GFP                                                                              This Study                                          N/A
  Software and Algorithms                                                                                                                      
  Bowtie2-2.2.6                                                                            [@R18]                                              RRID: SCR_005476; <https://github.com/BenLangmead/bowtie/>
  R package domainCalling                                                                  This Study                                          <https://github.com/TapscottLab/domainCalling>
  ChIPseeker/Bioconductor-3.5                                                              [@R39]                                              <https://www.bioconductor.org/packages/release/bioc/html/ChIPseeker.html>
  csaw/Bioconductor-3.5                                                                    [@R23]                                              <https://bioconductor.org/packages/release/bioc/html/csaw.html>
  Genomic Alignments/Bioconductor-3.5                                                      [@R19]                                              <https://bioconductor.org/packages/release/bioc/html/GenomicAlignments.html>
  edgeR/Bioconductor-3.5                                                                   [@R25]                                              RRID:SCR_012802; <http://bioconductor.org/packages/release/bioc/html/edgeR.html/>
  DESeq2/Bioconductor-3.5                                                                  [@R22]                                              RRID:SCR_000154; <http://bioconductor.org/packages/release/bioc/html/DESeq.html>
  Tophat-2.1.0                                                                             [@R33]                                              RRID:SCR_013035; <http://ccb.jhu.edu/software/tophat/index.shtml>
  Ensembl v88                                                                              [@R40]                                              RRID:SCR_002344; <http://www.ensembl.org//useast.ensembl.org/?redirectsrc=//www.ensembl.org%2F/>
  CRAN: ggplot2                                                                            [@R36]                                              RRID: SCR_014601; <https://cran.r-project.org/web/packages/ggplot2/index.html>

###### Highlights

-   The cleavage-stage transcription factor DUX4 induces histone variants H3.X and H3.Y

-   H3.X/Y incorporate into genes transcriptionally induced by DUX4

-   H3.X/Y incorporation results in enhanced re-activation of DUX4-regulated genes

-   H3.X/Y are necessary to amplify the DUX4 network in FSHD muscle cells
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